Buergofol Gmbh v. Omega Liner Company, Inc.

NOTE: This order is nonprecedential.
United States Court of Appeals
for the Federal Circuit
______________________
BUERGOFOL GMBH,
Plaintiff-Petitioner
v.
OMEGA LINER COMPANY, INC.,
Defendant-Respondent
______________________
2025-1817
______________________
Appeal from the United States District Court for the
District of South Dakota in No. 4:22-cv-04112-KES, Senior
Judge Karen E. Schreier.
______________________
ON PETITION AND MOTION
______________________
Before TARANTO, CUNNINGHAM, and STARK, Circuit
Judges.
PER CURIAM.
O R D E R
Buergofol GmbH petitions for a writ of mandamus
seeking to vacate the May 20, 2025 discovery-compelling
order of the United States District Court for the District of
South Dakota and also moves for a stay pending this court’s
Case: 25-1817 Document: 25 Page: 1 Filed: 07/22/2025

-- 1 of 5 --

BUERGOFOL GMBH v. OMEGA LINER COMPANY, INC. 2
consideration of the petition. Omega Liner Company, Inc.
opposes. Buergofol replies. Omega moves for leave to file
a sur-reply and supplemental appendix.
I.
Omega manufactures and sells ultraviolet cured-in-
place pipe liners used for pipe renovation. For some time,
Omega purchased the inner tubular films for its liners from
Buergofol, which generally asserts that it owns multiple
trade secrets related to the composition, structure, or man-
ufacture of the films. In particular, Buergofol asserts
trade-secret coverage for “Wax 40,” a special type of adhe-
sion promoter used for such a film. ECF No. 10-1 at 26.
In 2019, Omega stopped purchasing films from Buergo-
fol and started purchasing them from another supplier. In
2022, Buergofol filed the underlying action against Omega,
alleging infringement of U.S. Patent Nos. 9,657,882 and
8,794,269—specifically, that “all liners made by Omega of
diameter greater than 21 inches that were made using in-
ner film made by Buergofol infringe” claims of the patents.
Appx471.1 Omega responded with counterclaims seeking
declarations that it did not infringe, that the patents’
claims are invalid, and that the patents are unenforceable
because of inequitable conduct. Omega’s invalidity conten-
tions are based in part on alleged pre-priority-date sales of
liners from other manufacturers using Buergofol’s own
films, including a version of an inner liner that had wax
additive. SAppx603–632.2
A discovery dispute is at the center of this petition. The
dispute stems from a production request made by Omega
for documents related to the structure, composition, and
1 “Appx” page numbers refer to the appendix filed in
support of the petition, ECF No. 10-2.
2 “SAppx” page numbers refer to the supplemental
appendix filed with the response, ECF No. 19.
Case: 25-1817 Document: 25 Page: 2 Filed: 07/22/2025

-- 2 of 5 --

BUERGOFOL GMBH v. OMEGA LINER COMPANY, INC. 3
manufacture of the component parts of the films sold by
Buergofol to Omega, arguing that it needs the documents
to assess whether: (1) the use of Buergofol’s films with
Omega’s liners infringed each element of the asserted
claims; and (2) certain sales of other products using Buer-
gofol’s films before the critical date constituted prior art.
In 2023, the magistrate judge assigned to the case granted
Omega’s motion to compel production subject to the protec-
tive order’s designation of the material for attorney’s eyes
only (“AEO”) and denied Buergofol’s motion for an addi-
tional protective order. Buergofol then produced a declara-
tion and 21 pages of redacted manufacturing specifications,
but the district court found that production to be insuffi-
cient and ordered Buergofol to turn over all relevant mate-
rials. Buergofol objected and moved for a stay of
enforcement.
On May 20, 2025, after reviewing the withheld materi-
als in camera, the district court issued an order reaffirming
the prior rulings compelling Buergofol to produce the ma-
terials and denying its motion for a stay of enforcement of
that ruling. The district court recognized that the docu-
ments in question contained information that, if publicly
disclosed, could result in commercial harm to Buergofol.
Appx6. But it held that the materials should still be pro-
duced under the protective order’s provision limiting access
solely to Omega’s outside attorney. The court reasoned,
among other things, that “Buergofol put its films directly
at issue when it sued Omega and claimed that Omega lin-
ers using Buergofol film infringed the relevant patent,”
Appx9–10, and that there was a need to identify the char-
acteristics of certain films such as Wax 40, Appx7. This
petition followed.
II.
In the cases cited by Buergofol itself, courts have recog-
nized that trade-secret information is not immune from
discovery; instead, such material may be available upon a
Case: 25-1817 Document: 25 Page: 3 Filed: 07/22/2025

-- 3 of 5 --

BUERGOFOL GMBH v. OMEGA LINER COMPANY, INC. 4
showing of relevance and need for such information to pre-
pare for the litigation where the district court decides, in
its discretion, that the interests favoring discovery out-
weigh the harms to the trade secret’s owner. See In re Re-
mington Arms Co., Inc., 952 F.2d 1029, 1032 (8th Cir.
1991); accord Drone Techs., Inc. v. Parrot S.A., 838 F.3d
1283, 1299–1300 (Fed. Cir. 2016); cf. In re Micron Tech.
Inc., No. 2025-117, 2025 WL 615394, at *2 (Fed. Cir. Feb.
26, 2025) (denying mandamus petition seeking to prevent
limited discovery of source code). On mandamus, as rele-
vant here, we would disturb the district court’s determina-
tion only if we determined that there were “exceptional
circumstances amounting to . . . a clear abuse of discre-
tion.” Cheney v. U.S. Dist. Ct. for D.C., 542 U.S. 367, 380
(2004) (cleaned up).
Here, Buergofol has not shown a clear abuse of discre-
tion in the district court’s determination that Omega had
demonstrated need for the information and that the cur-
rent protective order was sufficient to protect Buergofol’s
interests. The court reasonably rejected Buergofol’s argu-
ment that the documents were irrelevant to infringement,
noting that Buergofol asserted infringement based on
Omega’s use of Buergofol’s products. Although Buergofol
now insists that it is no longer pursuing infringement
based on those products, Buergofol “has not made a cove-
nant not to sue,” Appx10 n.2, and, in any event, the court
reasonably found that the information at issue was also rel-
evant to Omega’s counterclaims (which asserted prior-art
invalidating sales of Buergofol’s products). The district
court further found that “Buergofol has failed to explain
why the current AEO provision in the protective order can-
not adequately protect Buergofol’s interests and maintain
its trade secrets,” noting that “Buergofol has already dis-
closed information pursuant to the protective order and no
issues have ensued.” Appx10–11. “[W]e are not prepared
to disturb the trial court’s balancing of the interests on lim-
ited mandamus review based merely on [Buergofol’s]
Case: 25-1817 Document: 25 Page: 4 Filed: 07/22/2025

-- 4 of 5 --

BUERGOFOL GMBH v. OMEGA LINER COMPANY, INC. 5
conjecture that an individual might violate the protective
order and subject themselves to appropriate sanctions.”
Micron, 2025 WL 615394, at *2.
Buergofol argues that Wax 40 was never used for the
films it sold to Omega and the relevant materials were cre-
ated after the critical dates for the patents, so that infor-
mation is irrelevant. But the district court had a
reasonable basis to reject Buergofol’s contentions. Omega
has asserted that the use of related wax films in non-party
products constitutes invalidating prior art sales. See
SAppx618. Given Buergofol’s apparent “double-speak”
with regard to its characteristics, Appx7, and disputes con-
cerning the existence of prior-art sales, the district court
committed no clear abuse of discretion in concluding that
Omega needed the information in question, at least so that
Buergofol “cannot dispute their validity and to straighten
out and reconcile Buergofol’s conflicting or unsupported
statements,” Appx8.
Accordingly,
IT IS ORDERED THAT:
(1) The petition is denied.
(2) Omega’s motion for leave to file a sur-reply and
supplemental appendix is granted. ECF Nos. 22-2 and 22-
3 are accepted for filing.
(3) Buergofol’s motion to stay is denied as moot.
July 22, 2025
Date
FOR THE COURT
Case: 25-1817 Document: 25 Page: 5 Filed: 07/22/2025

-- 5 of 5 --